Has James Palma, MD received payments from drug or device companies?

Yes. Drug and device makers reported $716 in general payments to James Palma, MD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Palma, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Palma, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Palma, MD

Gastroenterology · New York, NYNPI 1821114091

Payments from drug & device makers

$716in general payments, 2019–2025

Across 37 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$522
QOL Medical, LLC$52
Regeneron Healthcare Solutions, Inc.$44
Phathom Pharmaceuticals, Inc.$40
AbbVie$32
E.r. Squibb & Sons, L.L.C.$25

What the payments were for

Food & beverage$64690%
Education$7010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	27	$522
QOL Medical, LLC	2	$52
Regeneron Healthcare Solutions, Inc.	2	$44
Phathom Pharmaceuticals, Inc.	2	$40
AbbVie	2	$32
E.r. Squibb & Sons, L.L.C.	2	$25

How this compares

$716 in reported general payments places this provider in the 30th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024

$43,937

Medicare patients

173

Services billed

376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mesalamine	13	$8,384
Budesonide DrBudesonide	21	$5,401
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg	196	$3,444
Famotidine	112	$2,274
Omeprazole	96	$1,753
Budesonide EcBudesonide	11	$1,053
Pantoprazole Sodium	36	$419
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	23	$318

Paid to pharmacies, not to this prescriber.

Other gastroenterology in New York

David HudesmanNew York$3.6M
Ellen ScherlNew York$2.9M
Bruce SandsNew York$2.8M
Arun SwaminathNew York$2.7M
Sonal KumarNew York$2.3M
David Carr LockeNew York$2.1M
Arthur KornbluthNew York$1.9M
Ira JacobsonNew York$1.8M
James MarionNew York$1.7M
Jean Frederick ColombelNew York$1.6M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →